3-Pyridinesulfonamide, 5-bromo-N-(5-chloro-4-hydroxy-3-pyridinyl)-6-methoxy-
- CAS No.
- 1638200-22-2
- Chemical Name:
- 3-Pyridinesulfonamide, 5-bromo-N-(5-chloro-4-hydroxy-3-pyridinyl)-6-methoxy-
- Synonyms
- ABR-238901;3-Pyridinesulfonamide, 5-bromo-N-(5-chloro-4-hydroxy-3-pyridinyl)-6-methoxy-
- CBNumber:
- CB19313043
- Molecular Formula:
- C11H9BrClN3O4S
- Molecular Weight:
- 394.63
- MDL Number:
- MOL File:
- 1638200-22-2.mol
| Boiling point | 576.7±60.0 °C(Predicted) |
|---|---|
| Density | 1.830±0.06 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO : 33.33 mg/mL (84.46 mM; ultrasonic and warming and heat to 60°C) |
| form | Solid |
| pka | 2.17±0.50(Predicted) |
| color | Light brown to khaki |
3-Pyridinesulfonamide, 5-bromo-N-(5-chloro-4-hydroxy-3-pyridinyl)-6-methoxy- Chemical Properties,Uses,Production
Biological Activity
ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research[1][2][3]. ABR-238901 (30 mg/kg/day; gavage; for 3 weeks) causes less angiogenesis and less IL6 and IL10 in MDSCs[1]. ABR-238901 (30 mg/kg/day; gavage) in combination with Bortezomib (0.6 mg/kg; sc; 2 times/week) reduces tumor load compared with treatments of either agent alone[1]. ABR-238901 (30 mg/kg; IP for the first 3 d and thereafter continuously p.o.; daily; for 21 days) leads to gradual deterioration of cardiac function and accelerated left ventricular remodeling in C57BL/6NRJ mice with myocardial ischemia induced by permanent coronary artery ligation. Treatment with ABR-238901 during the first 3 days post-myocardial infarction (MI) restricts the inflammatory damage and promotes a reparatory environment[2].
References
[1]. Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5(10):839-846. [2]. Goran Marinkovi?, et al. S100A9 Links Inflammation and Repair in Myocardial Infarction. Circ Res. 2020 Aug 14;127(5):664-676. [3]. A. Schiopu, et al. Short-term blockade of the S100A8/A9 alarmin in the immediate post-myocardial infarction period inhibits acute myocardial inflammation and preserves myocardial repair. European Heart Journal, Volume 38, Issue suppl_1, August 2017, ehx504.
3-Pyridinesulfonamide, 5-bromo-N-(5-chloro-4-hydroxy-3-pyridinyl)-6-methoxy- Preparation Products And Raw materials
Raw materials
Preparation Products
3-Pyridinesulfonamide, 5-bromo-N-(5-chloro-4-hydroxy-3-pyridinyl)-6-methoxy- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Aladdin Scientific | +1-+1(833)-552-7181 | sales@aladdinsci.com | United States | 52927 | 58 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9707 | 58 |
| ShangHai ChuanQian Chemcial Technique Centre | 15869524721 | 3525679403@qq.com | China | 3721 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 23963 | 58 |
| Shanghai?Medlife?Pharm-Tech?Co.,?Ltd | 021-59167510 18117107507 | vip@med-life.cn | China | 5012 | 58 |
| RD International Technology Co., Limited | 18024082417 | market@ubiochem.com | China | 9274 | 58 |